Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $1.24 per share a year ago.